Aldeyra Therapeutics Reports the US FDA Acceptance of NDA for Priority Review of ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma
Shots:
- The US FDA has accepted the NDA for Priority Review of ADX-2191 (methotrexate injection) for PVRL. The US FDA’s decision is expected on June 2023 with the planning to launch ADX-2191 in the US in H2’23
- The NDA submission was based on the combination of more than three decades of published literature on the safety & efficacy of ADX‑2191 along with the safety data from the P-III trial (GUARD). The P-III trial (GUARD) results showed no safety signals & were found to be well tolerated with no observed treatment-emergent serious AEs
- ADX-2191 is a sterile, non-compounded IVT formulation of methotrexate for specific rare retinal diseases. The therapy received ODD from the US FDA for PVR, PVRL, and retinitis pigmentosa
Ref: Aldeyra | Image: Aldeyra
Related Post:- Aldeyra Therapeutics Reports the US FDA Acceptance of NDA for Reproxalap to Treat Dry Eye Disease
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
